[{"id":"bf5cc737-c6cb-4899-99a5-c61a24a807ae","acronym":"SJ901","url":"https://clinicaltrials.gov/study/NCT04923126","created_at":"2021-06-11T18:56:10.986Z","updated_at":"2025-02-25T12:37:53.246Z","phase":"Phase 1/2","brief_title":"SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma","source_id_and_acronym":"NCT04923126 - SJ901","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" BRAF • NF1 • PTPN11 • MYBL1","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • NF1 • PTPN11 • MYBL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 06/21/2021","start_date":" 06/21/2021","primary_txt":" Primary completion: 06/01/2031","primary_completion_date":" 06/01/2031","study_txt":" Completion: 06/01/2031","study_completion_date":" 06/01/2031","last_update_posted":"2025-02-24"},{"id":"e6419ea6-12ef-460f-8597-b07958498262","acronym":"IMMUNOMEK","url":"https://clinicaltrials.gov/study/NCT05937906","created_at":"2023-07-10T13:08:51.069Z","updated_at":"2025-02-25T14:09:51.533Z","phase":"Phase 1/2","brief_title":"Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 \u003c 50 %.","source_id_and_acronym":"NCT05937906 - IMMUNOMEK","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Gomekli (mirdametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/30/2024","start_date":" 07/30/2024","primary_txt":" Primary completion: 05/25/2028","primary_completion_date":" 05/25/2028","study_txt":" Completion: 05/25/2028","study_completion_date":" 05/25/2028","last_update_posted":"2025-02-18"},{"id":"638d5845-a2b6-4c6b-b8df-41704f0f7049","acronym":"MIRV","url":"https://clinicaltrials.gov/study/NCT06666348","created_at":"2025-02-25T15:37:40.797Z","updated_at":"2025-02-25T15:37:40.797Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK","source_id_and_acronym":"NCT06666348 - MIRV","lead_sponsor":"C17 Council","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib) • vinblastine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 04/01/2030","primary_completion_date":" 04/01/2030","study_txt":" Completion: 04/01/2035","study_completion_date":" 04/01/2035","last_update_posted":"2025-02-11"},{"id":"a6924d5b-de24-40e2-b106-96da6cb8e6d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06693284","created_at":"2025-02-25T15:37:46.378Z","updated_at":"2025-02-25T15:37:46.378Z","phase":"Phase 1","brief_title":"A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]","source_id_and_acronym":"NCT06693284","lead_sponsor":"University of Minnesota","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib) • Zolinza (vorinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-01-14"},{"id":"6440bd6a-571a-4ca7-8a63-d023b758b108","acronym":"","url":"https://clinicaltrials.gov/study/NCT03905148","created_at":"2023-04-15T20:09:41.975Z","updated_at":"2025-02-25T15:34:24.106Z","phase":"Phase 1","brief_title":"Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors","source_id_and_acronym":"NCT03905148","lead_sponsor":"BeiGene","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib) • lifirafenib (BGB-283)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-10-26"},{"id":"5e4005e8-2746-47c2-b8df-66fc536bfe6d","acronym":"RENEU","url":"https://clinicaltrials.gov/study/NCT03962543","created_at":"2021-01-18T19:29:52.226Z","updated_at":"2025-02-25T15:34:26.121Z","phase":"Phase 2","brief_title":"MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas","source_id_and_acronym":"NCT03962543 - RENEU","lead_sponsor":"SpringWorks Therapeutics, Inc.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 09/29/2019","start_date":" 09/29/2019","primary_txt":" Primary completion: 09/20/2023","primary_completion_date":" 09/20/2023","study_txt":" Completion: 05/23/2025","study_completion_date":" 05/23/2025","last_update_posted":"2024-10-17"},{"id":"3d58d724-7b7a-4521-94a7-0e3dc4880d42","acronym":"","url":"https://clinicaltrials.gov/study/NCT05054374","created_at":"2021-09-23T17:53:02.260Z","updated_at":"2025-02-25T15:35:18.664Z","phase":"Phase 1/2","brief_title":"A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer","source_id_and_acronym":"NCT05054374","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124","tags":["HER-2 • ER • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Gomekli (mirdametinib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 10/26/2023","primary_completion_date":" 10/26/2023","study_txt":" Completion: 10/26/2023","study_completion_date":" 10/26/2023","last_update_posted":"2024-07-09"},{"id":"1b012258-7d95-49e4-ba35-e4391303b6ed","acronym":"Mirda","url":"https://clinicaltrials.gov/study/NCT06159166","created_at":"2023-12-06T20:17:34.783Z","updated_at":"2025-02-25T15:36:42.309Z","phase":"Phase 1/2","brief_title":"Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).","source_id_and_acronym":"NCT06159166 - Mirda","lead_sponsor":"Johns Hopkins University","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Gomekli (mirdametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 02/12/2024","start_date":" 02/12/2024","primary_txt":" Primary completion: 11/15/2027","primary_completion_date":" 11/15/2027","study_txt":" Completion: 11/15/2028","study_completion_date":" 11/15/2028","last_update_posted":"2024-04-25"},{"id":"51c1d51d-fdcf-48b3-89a6-bab02f099fa5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02022982","created_at":"2021-01-18T09:16:01.874Z","updated_at":"2025-02-25T15:32:58.874Z","phase":"Phase 1","brief_title":"PALBOCICLIB + PD-0325901 for NSCLC \u0026 Solid Tumors","source_id_and_acronym":"NCT02022982","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Gomekli (mirdametinib)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2024-03-19"},{"id":"726018f8-a8bb-47b9-b507-183575dc2a24","acronym":"MErCuRIC1","url":"https://clinicaltrials.gov/study/NCT02510001","created_at":"2021-01-18T12:07:19.285Z","updated_at":"2025-02-25T15:33:28.804Z","phase":"Phase 1","brief_title":"MEK and MET Inhibition in Colorectal Cancer","source_id_and_acronym":"NCT02510001 - MErCuRIC1","lead_sponsor":"University of Oxford","biomarkers":" KRAS • MET • NRAS","pipe":" | ","alterations":" MET amplification • MET overexpression • RAS mutation • MET expression","tags":["KRAS • MET • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RAS mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Mektovi (binimetinib) • Gomekli (mirdametinib)"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 12/03/2018","primary_completion_date":" 12/03/2018","study_txt":" Completion: 12/03/2018","study_completion_date":" 12/03/2018","last_update_posted":"2021-07-13"},{"id":"0cad5312-7415-4f0d-a10f-ebfe1e20c2ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT02096471","created_at":"2021-01-18T09:40:41.432Z","updated_at":"2025-02-25T15:33:06.432Z","phase":"Phase 2","brief_title":"MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1","source_id_and_acronym":"NCT02096471","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 08/09/2017","primary_completion_date":" 08/09/2017","study_txt":" Completion: 08/01/2018","study_completion_date":" 08/01/2018","last_update_posted":"2019-01-10"},{"id":"e1bf3faa-d8a3-4dd4-b0b8-8f5accb5cfa1","acronym":"M13DAP","url":"https://clinicaltrials.gov/study/NCT02039336","created_at":"2021-01-18T09:21:38.832Z","updated_at":"2025-02-25T15:33:00.773Z","phase":"Phase 1/2","brief_title":"Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC","source_id_and_acronym":"NCT02039336 - M13DAP","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS exon 2 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Vizimpro (dacomitinib) • Gomekli (mirdametinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 35","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2018-08-27"}]